Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ: ILMN) elected David P. King, former Labcorp Executive Chairman and CEO, to its Board of Directors, effective immediately after the 2026 annual shareholder meeting.
Illumina highlights his regulatory, diagnostics, and healthcare expertise as it advances its clinical genomics strategy. King succeeds retiring directors Frances Arnold, Robert Epstein, and Gary Guthart.
Illumina (NASDAQ: ILMN) released its 2025 Corporate Responsibility Report, emphasizing expanded access to genomics and global impact. Highlights include sequencing over 10 human genomes per minute in 2025, major sustainability gains, workforce equity, large-scale community engagement, and new product launches that broaden research, clinical, and population health applications.
Illumina (Nasdaq: ILMN) reported Q1 FY2026 revenue of $1.09B (+4.8% YoY) with GAAP operating margin of 19.2%, non-GAAP operating margin of 21.9%, GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15.
Free cash flow was $251M. On April 28, the board authorized an additional $1.5B share repurchase and raised full‑year revenue and non‑GAAP EPS guidance.
Illumina (NASDAQ: ILMN) on April 16, 2026 launched DRAGEN v4.5, expanding germline, oncology, and multiomic analysis with support for TruPath Genome and the 5-base assay.
Key gains: ~20% reduction in germline small-variant errors versus v4.4, expanded pangenome including Middle Eastern genomes, structural-variant calling for 5-base, ML-driven somatic calling, >90% FFPE SNV false-positive reduction, and oncovirus detection (100% expected detections plus 18 additional).
Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a data partnership on April 14, 2026 to analyze 100,000 whole genomes from pediatric patients. The cloud-based platform uses DRAGEN v4.4 and Illumina Connected Analytics to enable cross-cohort, real-time genomic discovery for pediatric cancer and rare disease.
The unified dataset will be available via the Kids First Data Resource Center and support ARPA-H's Pediatric Care eXpansion to link data across >200 pediatric institutions, aiming to accelerate research translation and shorten clinical care timelines.
Illumina (NASDAQ:ILMN) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. A conference call and live webcast with CEO Jacob Thaysen, PhD, and CFO Ankur Dhingra will follow at 1:30 pm PT / 4:30 pm ET. A replay will be posted on the company's investor website and remain available for at least 30 days.
Illumina (NASDAQ: ILMN) announced Board changes on April 2, 2026: Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board in connection with the company's upcoming annual meeting, and the Board has nominated David P. King for election as a director.
Chair Scott Gottlieb thanked the retiring directors for their service and said David King brings operating experience, public company board leadership, and regulatory insight across healthcare and life sciences to support Illumina's next phase of growth and genomics integration into medicine.
Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.
Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).
Illumina (NASDAQ: ILMN) on March 16, 2026 announced a strategic consortium with Veritas Genetics Powered By Fuze Health to integrate whole-genome sequencing into preventive care via health plans. The collaboration combines Illumina sequencing and informatics with Veritas patient-ready reporting to enable earlier risk detection, integrated care pathways, and a consented clinical-genomics dataset.
The program targets hereditary cancer, cardiometabolic risk, and medication response, and includes sample collection, confirmatory testing, counseling, and industry data partnerships.
Illumina (NASDAQ: ILMN) and NashBio announced expansion of the Alliance for Genomic Discovery on March 5, 2026: the core dataset grows to 312,000 whole genomes with longitudinal clinical data and a new multiomic initiative will add 50,000 whole genomes paired with proteomic data using Illumina Protein Prep.
Regeneron Genetics Center joins as the tenth member, and GSK is among the first participants in the proteomics expansion. Illumina's recent acquisition of SomaLogic proteomics technologies is cited as enabling the multiomic effort.